China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate-March 2024-www.financetom.com

China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate

Jan 13, 2025 6:29 AM

Jan 13 (Reuters) - Simcere Pharmaceutical ( SMHGF ) said

on Monday its unit had granted U.S. drugmaker AbbVie ( ABBV )

the option to license its new blood cancer drug candidate

outside China.

Under the deal, AbbVie ( ABBV ) will pay Simcere up to $1.06 billion,

along with royalties on sales outside China. AbbVie ( ABBV ) would

receive royalties on sales within China.

Previous page： Market Chatter: Mastercard to Discontinue Manual Card Entry for Online Payments in Europe by 2030 Next page： General Motors' Board Approves $6 Billion Share Repurchase Program

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Market Chatter: Mastercard to Discontinue Manual Card Entry for Online Payments in Europe by 2030

Jun 11, 2024

07:30 AM EDT, 06/11/2024 (MT Newswires) -- Mastercard ( MA ) will not require Europeans to provide their card numbers manually when checking out online starting in 2030, CNBC reported Tuesday. A randomly-generated token will replace the traditional 16-digit card entry, no matter what platform or device the customer is using, according to the report. (Market Chatter news is derived...

General Motors' Board Approves $6 Billion Share Repurchase Program

Jun 11, 2024

07:33 AM EDT, 06/11/2024 (MT Newswires) -- General Motors ( GM ) said Tuesday that its board of directors has approved a new share repurchase program to buy back up to $6 billion of the company's outstanding common stock. The company launched a $10 billion accelerated share repurchase program in November 2023, with about $1.4 billion in remaining capacity under...

Sage Therapeutics Says Phase 2 SURVEYOR Trial Met Primary Endpoint

Jun 11, 2024

07:39 AM EDT, 06/11/2024 (MT Newswires) -- Sage Therapeutics ( SAGE ) said Tuesday that its phase 2 SURVEYOR trial met its primary endpoint, exhibiting a statistically significant difference between healthy participants and patients with Huntington's disease before treatment with the investigational drug dalzanemdor or placebo. Dalzanemdor was found to be safe and generally well-tolerated in the trial, which was...

Market Chatter: CVS Store-Brand Medications Face Quality Concerns and Higher Recall Rates

Jun 11, 2024

07:41 AM EDT, 06/11/2024 (MT Newswires) -- CVS Health ( CVS ) store-brand medications have a higher recall rate than competitors due to quality issues at factories, including contaminated water in production, drugs being too potent and manufacturing oversight, Bloomberg reported on Tuesday. Over the past decade, CVS's store-brand medications have been recalled about two times more than those from...